Infectious risk of biological drugs versus conventional systemic treatments in moderate to severe psoriasis

Being a woman (HR = 1.23), benefit from the Universal Health Coverage (HR = 1.44), suffering from chronic hepatitis B or C (HR = 2.74), history of neoplasia (HR = 1.70), a previous infectious event during the observation period (HR = 1.74), and the number of drugs consumed during the observation per...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2015-08, Vol.37 (8), p.e4-e4
Main Authors: Couderc, S, Bourrel, R, Paul, C, Montastruc, J.L, Lapeyre-Mestre, M, Sommet, A
Format: Article
Language:English
Subjects:
Biological products
Drugs
Infections
Internal Medicine
Medical Education
Psoriasis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Being a woman (HR = 1.23), benefit from the Universal Health Coverage (HR = 1.44), suffering from chronic hepatitis B or C (HR = 2.74), history of neoplasia (HR = 1.70), a previous infectious event during the observation period (HR = 1.74), and the number of drugs consumed during the observation period (HR = 1.03) significantly increased the risk of infection.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.020